The History of Alström Syndrome: 1959 to Today

The story of Alström Syndrome spans more than 65 years — from a Swedish psychiatrist's careful clinical descriptions in 1959, through decades of clinical refinement, to the discovery of the ALMS1 gene in 2002 and the active gene-therapy research underway in 2026. This article traces that history and explains how each era shaped the care families have today.

The Swedish psychiatrist Carl-Henry Alström and his colleagues B. Hallgren, L. Nilsson, and H. Åsander published the original description of the syndrome in 1959.¹ They reported on three patients from a single family with:

• Childhood blindness from retinal degeneration
• Sensorineural deafness
• Diabetes mellitus
• Obesity

The careful clinical observation distinguished this constellation from other recognized retinal-dystrophy syndromes of the time. The syndrome carries Carl-Henry Alström's name in recognition of this work.

Following the original description, additional case reports appeared in the medical literature. Through the 1960s and 1970s, the picture expanded:

• Cardiomyopathy was recognized as a feature (initially described in some patients in the 1970s)
• Liver and kidney involvement were added to the clinical picture
• The autosomal recessive inheritance pattern was confirmed
• The condition was increasingly distinguished from related ciliopathies like Bardet-Biedl Syndrome

By the 1980s, the multisystem nature of Alström was well-recognized in the medical literature, though the underlying cause remained unknown.

Gene mapping techniques in the 1990s allowed researchers to begin localizing the gene responsible. Linkage studies in families with multiple affected members narrowed the location to chromosome 2p13. This was a foundation for the next major step.²

In 2002, two research groups simultaneously identified mutations in the ALMS1 gene as the cause of Alström Syndrome.³ ⁴ This was a transformational moment:

• Definitive molecular diagnosis became possible
• Carrier testing became available
• Family planning options expanded
• Research could now target a specific gene

The gene was found to be unusually large — 23 exons, encoding a protein of approximately 4,169 amino acids. The size would later prove relevant to therapeutic development.

In the years after gene identification:

• The protein's localization to the basal body of cilia was established, placing Alström in the broader family of ciliopathies
• More genetic variants were catalogued
• Animal models — particularly the Alms1 knockout mouse and the spontaneous "fat aussie" (foz) mouse — became important research tools
• Clinical natural history was better characterized

This decade also saw the establishment of patient organizations playing increasingly central roles:

• Alström Syndrome International (ASI) — founded by families with affected children
• Alström Syndrome UK (ASUK) — providing UK-specific advocacy and support
• Alström Angels — additional fundraising and family-support organization

Several developments improved care delivery:

• The NHS Highly Specialised Service for Alström was established at Birmingham
• Alström Syndrome International established the Jan D. Marshall Center of Excellence at GBMC in 2015
• A pediatric multidisciplinary clinic was added at Indiana University
• The European Reference Network for rare eye diseases (ERN-EYE) developed cross-border expertise

In 2020, the international consensus management guidelines were published in Orphanet Journal of Rare Diseases — the most comprehensive single document for clinicians caring for patients with Alström.⁵ These guidelines drew together expertise from European, US, and other centers and remain a reference for surveillance and treatment.

The current decade has seen:

• Active gene-therapy research, despite the technical challenges of the large ALMS1 gene
• Expansion of natural-history studies
• Larger international cohort studies — including a 2025 study of 127 Chinese patients identifying many novel variants⁶
• Earlier diagnosis through expanded genetic testing
• Patient registries with international participation
• Increasing public awareness

The UK has launched a 3-year project starting in 2025 to advance research at the University of Birmingham, in collaboration with multiple specialist centers. China's National Center for Molecular Medicine in Shanghai is conducting gene therapy work. Multiple academic centers worldwide are advancing different aspects of the science.

Beyond the original Alström research team:

• Jan D. Marshall — long-time research leader at The Jackson Laboratory whose work led to important advances; the GBMC Center of Excellence carries her name
• Patrizia Maffei and Pietro Maffei — Italian researchers contributing extensively to clinical and basic-science understanding
• Richard Paisey — UK clinician central to the Highly Specialised Service development
• Many others, including the parents and patients who have advanced understanding through registry participation, advocacy, and research engagement

Compared to 1959:

• The clinical picture is fundamentally similar — the same multi-system condition affects the same body systems
• Diagnosis is now molecular, not purely clinical
• Surveillance and treatment have improved substantially
• Patient organizations connect families globally
• Mental health support is increasingly recognized
• Adult outcomes are better than they were
• Research is more active

What hasn't changed:

• Alström remains a serious progressive condition
• No cure exists
• Care is multidisciplinary
• Family experience involves significant adaptation

The trajectory suggests:

• Gene therapy may emerge in the next decade or so
• Better understanding of mechanisms will improve treatments for downstream complications
• Earlier diagnosis will continue to improve
• Connected international networks will accelerate research
• Patient-organization advocacy will continue shaping the field

The next chapters of Alström history will be written by researchers, clinicians, and — most importantly — patients and families participating in research and advocating for progress.

• What Is Alström Syndrome? Simple Family Guide
• Alström Syndrome Genetics: ALMS1 Gene Explained
• Alström Syndrome Research and Clinical Trials in 2026
• Alström Syndrome Support Organizations
• Alström Syndrome Centers of Excellence

April 30, 2026.